Presenter of 10 Presentations
Reimagining prevention: the population approach
Introduction
An App to guide clinical care- what is it and how should we use it
What’s been achieved and what more is needed - real world evidence
The epidemiology of DM and obesity and risk of ASCVD
Welcome from EAS President
Young Investigator Award
Overall Concept
Introduction to Anitschkow Prize winner, Prof Nordestgaard
OBICETRAPIB LOWERS LDL-C IN PATIENTS ON HIGH INTENSITY STATINS: RESULTS FROM THE ROSE TRIAL (NCT04753606).
Abstract
Background and Aims
Background: As guidelines now recommend lower LDL-C goals, means that many patients require additional lipid lowering therapies (LLT) to attain risk based LDL-C goals despite use of high intensity statins (HIS). Cost and/or efficacy of current LLT options have limited their uptake in clinical practice. Mendelian randomization and RCT trial data support CETP inhibition as a validated target to reduce LDL-C and cardiovascular risk. Safety and efficacy concerns have to date limited the development of CETPi. Previously the selective CETPi obicetrapib demonstrated LDL-C lowering up to 45% as monotherapy.
Aims: To assess the effects of obicetrapib on LDL-C and lipid parameters in patients on HIS.
Methods
Methods: 120 patients with LDL-C ≥70 mg/dL, despite HIS, were randomized to obicetrapib 5 or 10 mg or placebo for 8 weeks. The primary endpoint was percent change in LDL-C, secondary endpoints included changes in other lipids, exploratory analyses evaluated goal attainment.
Results
Results: Obicetrapib produced dose-dependent lowering of LDL-C, ApoB and non-HDL-C (up to 50.8%, 29.8% and 44.4% respectively, P<0.0001 for each, Table). Approximately 2/3 of patients achieved LDL-C < 55mg/dl when Obicetrapib was added to HIS vs PL. Fewer patients in the OBI arms experienced treatment emergent adverse events vs placebo (26 vs 48%) with no clinically significant changes in laboratory parameters, vital signs, or physical examinations.
Conclusions
Conclusion: Obicetrapib 5 and 10 mg produced robust decreases in LDL-C, ApoB and Non-HDL-C with greater attainment of lipid goals in the majority of patients treated with HIS and was well tolerated.